drugset
drugset / Trial / NCT07452822

Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease

NCT07452822 ↗

Phase 1/2 Not yet recruiting 54 enrolled Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

A Study on the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis

Timeline

Start
2026-02-20
Primary completion
2027-03-30
Completion
2028-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 500000 cells Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 2.5e+06 cells Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+06 cells Other

Indications

No indication recorded.